Publications

• Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer.

  (Tsai S, George B, Wittmann D, Ritch PS, Krepline AN, Aldakkak M, Barnes CA, Christians KK, Dua K, Griffin M, Hagen C, Hall WA, Erickson BA, Evans DB.) Ann Surg. 2020 04;271(4):740-747 PMID: 30312198 SCOPUS ID: 2-s2.0-85082099572 10/13/2018

• Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice?

  (Krepline AN, Bliss L, Geurts J, Akinola I, Christians KK, George B, Ritch PS, Hall WA, Erickson BA, Evans DB, Tsai S.) J Gastrointest Surg. 2020 Feb;24(2):235-242 PMID: 31745905 SCOPUS ID: 2-s2.0-85076028351 11/21/2019

• Persistent/Recurrent Primary Hyperparathyroidism: Does the Number of Abnormal Glands Play a Role?

  (Mazotas IG, Yen TWF, Doffek K, Shaker JL, Carr AA, Evans DB, Wang TS.) J Surg Res. 2020 02;246:335-341 PMID: 31635835 SCOPUS ID: 2-s2.0-85073829359 10/23/2019

• Confirmation of Parathyroid Tissue: Are Surgeons Aware of New and Novel Techniques?

  (Coan KE, Yen TWF, Carr AA, Evans DB, Wang TS.) J Surg Res. 2020 02;246:139-144 PMID: 31569035 SCOPUS ID: 2-s2.0-85072649600 10/01/2019

• Management of Acute Cholecystitis during Neoadjuvant Therapy in Patients with Pancreatic Adenocarcinoma.

  (Jariwalla NR, Khan AH, Dua K, Christians KK, Clarke CN, Aldakkak M, George B, Tutton S, Rilling W, Erickson B, Evans DB, Tsai S.) Ann Surg Oncol. 2019 Dec;26(13):4515-4521 PMID: 31641946 SCOPUS ID: 2-s2.0-85074492297 10/24/2019

• Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial.

  (Wei AC, Ou FS, Shi Q, Carrero X, O'Reilly EM, Meyerhardt J, Wolff RA, Kindler HL, Evans DB, Deshpande V, Misdraji J, Tamm E, Sahani D, Moore M, Newman E, Merchant N, Berlin J, Goff LW, Pisters P, Posner MC.) Ann Surg Oncol. 2019 Dec;26(13):4489-4497 PMID: 31418130 PMCID: PMC6868305 SCOPUS ID: 2-s2.0-85070951976 08/17/2019

• Goals of Treatment Sequencing for Localized Pancreatic Cancer.

  (Evans DB, Kamgar M, Tsai S.) Ann Surg Oncol. 2019 Nov;26(12):3815-3819 PMID: 31493126 SCOPUS ID: 2-s2.0-85073126378 09/08/2019

• Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery.

  (Barnes CA, Chavez MI, Tsai S, Aldakkak M, George B, Ritch PS, Dua K, Clarke CN, Tolat P, Hagen C, Hall WA, Erickson BA, Evans DB, Christians KK.) Surgery. 2019 09;166(3):277-285 PMID: 31272811 SCOPUS ID: 2-s2.0-85068174272 07/06/2019

• Editorial: Small, asymptomatic, nonfunctioning pancreatic neuroendocrine tumors: Observation becoming standard of care?

  (Clarke CN, Evans DB.) Surgery. 2019 08;166(2):164-165 PMID: 31097321 SCOPUS ID: 2-s2.0-85065533808 05/18/2019

• Distal splenorenal and mesocaval shunting at the time of pancreatectomy.

  (Chavez MI, Tsai S, Clarke CN, Aldakkak M, Griffin MO, Khan AH, Ritch PS, Erickson BA, Evans DB, Christians KK.) Surgery. 2019 02;165(2):298-306 PMID: 30471779 SCOPUS ID: 2-s2.0-85056892124 11/26/2018

• What Makes a Pancreatic Cancer Resectable?

  (Evans DB.) Am Soc Clin Oncol Educ Book. 2018 May 23;38:300-305 PMID: 30231408 09/21/2018

• Pancreatic neuroendocrine tumors

  (Yao JC, Clarke CN, Evans DB.) DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 16 November 2018:1353-1367 SCOPUS ID: 2-s2.0-85061201430 11/16/2018